Buy & Sell Vertex Pharmaceuticals Incorporated (VRTX) – Vertex Pharmaceuticals Incorporated Price Today
Aura AI Summary
Key Stats
- $120.61BMarket Cap
- HealthSector
- -6.2%3M Drawdown
- $115.35BEnterprise Value
- -Dividend Yield
- 92% Buy | 8% SellTrading Activity
- 106 daysTypical Hold Time
Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $120.61B, with an enterprise value of $115.35B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $499.17, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -6.2%, reflecting recent price volatility. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 106 days, indicating typical investor behavior on the platform.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
Global cable assembly market to reach $348.66B by 2035, driven by high-speed connectivity and digital infrastructure growth.
The global cable assembly market, valued at $194.54 billion in 2025, is projected to grow to $348.66 billion by 2035 at a CAGR of 6.03%. Growth is fueled by rising demand for high-speed connectivity, 5G networks, cloud computing, and digital infrastr...
Nyrstar shareholders petition court to appoint interim administrator amid ongoing legal disputes.
Certain shareholders of Nyrstar NV have filed a petition with the Antwerp Enterprise Court requesting the appointment of a provisional administrator or an ad hoc trustee to manage the company for at least 12 months. This move is part of ongoing legal...
Bloodstream infection testing market to grow to $1.4B by 2035, driven by rapid diagnostics and sepsis detection demand.
The global bloodstream infection testing market is projected to grow from $876.49 million in 2025 to $1.4 billion by 2035, at a CAGR of 4.8%. Growth is fueled by rising bloodstream infection cases, increased sepsis hospitalizations, and wider adoptio...